drugset
drugset / Trial / NCT06892379

A Study of HS-20110 in Participants With Advanced Solid Tumors

NCT06892379 ↗

Phase 1 Recruiting 475 enrolled Hansoh BioMedical R&D Company Hoffmann-La Roche · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors

Timeline

Start
2025-02-26
Primary completion
2026-12-31
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-20110 Unknown — Intravenous

Indications

cancer